2,4-Pyrimidinediamine, N4-(8-methyl-4-cinnolinyl)-N2-[4-(4-morpholinyl)phenyl]- manufacturers
- ALK5-IN-33
-
- $1980.00
-
2026-07-27
- CAS:2785430-89-7
- Purity:
- Supply Ability: 10g
|
| | 2,4-Pyrimidinediamine, N4-(8-methyl-4-cinnolinyl)-N2-[4-(4-morpholinyl)phenyl]- Basic information |
| | 2,4-Pyrimidinediamine, N4-(8-methyl-4-cinnolinyl)-N2-[4-(4-morpholinyl)phenyl]- Chemical Properties |
| Boiling point | 690.5±65.0 °C(Predicted) | | density | 1.341±0.06 g/cm3(Predicted) | | pka | 6.00±0.40(Predicted) |
| | 2,4-Pyrimidinediamine, N4-(8-methyl-4-cinnolinyl)-N2-[4-(4-morpholinyl)phenyl]- Usage And Synthesis |
| Uses | ALK5-IN-33 (Compound EX-10) is a selective, orally active ALK-5 inhibitor with an IC50 ≤10 nM[1]. | | in vivo | ALK-IN-33 (Compound EX-10) (10-100 mg/kg; i.g.; once) reduces the phospho SMAD2 levels in a dose dependent fashion in A549 xenograft model in mice[1]. | Animal Model: | Female athymic nude mice, A549 xenograft model[1] | | Dosage: | 10, 50, 75 and 100 mg/kg | | Administration: | Oral gavage, once
| | Result: | Reduced the phospho SMAD2 levels (p-SMAD2) in a dose dependent fashion. |
| | IC 50 | ALK5: ≤10 nM (IC50); ALK2 | | References | [1] Bettina FRANZ, et al. Alk-5 inhibitors and uses thereof. Patent WO2022126133A1. |
| | 2,4-Pyrimidinediamine, N4-(8-methyl-4-cinnolinyl)-N2-[4-(4-morpholinyl)phenyl]- Preparation Products And Raw materials |
|